Alex Thurman Sells 10,000 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS) CFO Alex Thurman sold 10,000 shares of the company’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $155.00, for a total transaction of $1,550,000.00. Following the completion of the transaction, the chief financial officer owned 43,681 shares in the company, valued at approximately $6,770,555. The trade was a 18.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Glaukos Stock Up 0.0%

GKOS stock traded up $0.04 during trading on Monday, hitting $152.76. 442,217 shares of the stock traded hands, compared to its average volume of 832,877. The stock has a market cap of $8.97 billion, a price-to-earnings ratio of -46.57 and a beta of 0.75. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.43 and a quick ratio of 4.73. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $156.60. The firm’s 50 day moving average is $132.67 and its two-hundred day moving average is $120.98.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.12. The business had revenue of $150.57 million during the quarter, compared to analysts’ expectations of $137.00 million. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The business’s revenue for the quarter was up 41.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.22) earnings per share. On average, sell-side analysts anticipate that Glaukos Corporation will post -0.57 EPS for the current year.

Hedge Funds Weigh In On Glaukos

Several institutional investors have recently made changes to their positions in the business. Wealth Alliance LLC lifted its position in shares of Glaukos by 4.5% during the first quarter. Wealth Alliance LLC now owns 2,297 shares of the medical instruments supplier’s stock worth $247,000 after purchasing an additional 98 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Glaukos by 9.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier’s stock worth $158,000 after purchasing an additional 122 shares during the last quarter. Larson Financial Group LLC increased its stake in Glaukos by 62.0% in the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after buying an additional 132 shares during the period. CWM LLC increased its stake in Glaukos by 25.2% in the 4th quarter. CWM LLC now owns 710 shares of the medical instruments supplier’s stock worth $80,000 after buying an additional 143 shares during the period. Finally, Commonwealth Equity Services LLC increased its stake in Glaukos by 1.7% in the 4th quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier’s stock worth $947,000 after buying an additional 144 shares during the period. Institutional investors own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on GKOS. Stifel Nicolaus set a $170.00 price objective on shares of Glaukos in a report on Thursday, April 30th. JPMorgan Chase & Co. increased their target price on Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a report on Tuesday, April 21st. William Blair restated an “outperform” rating on shares of Glaukos in a research note on Tuesday, May 26th. Finally, Wall Street Zen raised Glaukos from a “hold” rating to a “buy” rating in a report on Saturday, July 4th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $151.77.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.